Influence of vitamin C supplementation on oxidative and immune changes after an ultramarathon

DAVID C. NIEMAN,1 DRU A. HENSON,1 STEVE R. McNANUTY,1 LISA McANULTY,1 NATHANIEL S. SWICK,1 ALAN C. UTTER,1 DEBRA M. VINCI,1 SHANNON J. OPIELA,1 AND JASON D. MORROW2

1Departments of Health, Leisure, and Exercise Science, and Biology, Appalachian State University, Boone, North Carolina 28608; 2Departments of Medicine and Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232

Received 18 September 2001; accepted in final form 16 January 2002

Nieman, David C., Dru A. Henson, Steve R. McNanulty, Lisa McNanulty, Nathaniel S. Swick, Alan C. Utter, Debra M. Vinci, Shannon J. Opiela, and Jason D. Morrow. Influence of vitamin C supplementation on oxidative and immune changes after an ultramarathon. J Appl Physiol 92: 1970–1977, 2002.—The purpose of this randomized study was to measure the influence of vitamin C (n = 15 runners) compared with placebo (n = 13 runners) supplementation on oxidative and immune changes in runners competing in an ultramarathon race. During the 7-day period before the race and on race day, subjects ingested in randomized, double-blind fashion 1,500 mg/day vitamin C or placebo. On race day, blood samples were collected 1 h before race, after 32 km of running, and then again immediately after race. Subjects in both groups maintained an intensity of ~75% maximal heart rate throughout the ultramarathon race and ran a mean of 69 km (range: 48–80 km) in 9.8 h (range: 5–12 h). Plasma ascorbic acid was markedly higher in the vitamin C group compared with placebo group prerace and rose more strongly in the vitamin C group during the race (post-race: 3.21 ± 0.29 and 1.28 ± 0.12 μg/100 μl, respectively, P < 0.001). No significant group or interaction effects were measured for lipid hydroperoxide, F2-isoprostane, immune cell counts, plasma interleukin (IL)-6, IL-10, IL-1-receptor antagonist, or IL-8 concentrations, or mitogen-stimulated lymphocyte proliferation and IL-2 and IFN-γ production. These data indicate that vitamin C supplementation in carbohydrate-fed runners does not serve as a countermeasure to oxidative and immune changes during or after a competitive ultramarathon race.

interleukins; ascorbic acid; lymphocytes; isoprostanes; lipid hydroperoxide

OF ALL ESSENTIAL NUTRIENTS, vitamin C has generated the greatest interest for its potential influence on immune function and host defense (11). Vitamin C supplements have been shown to alter many different indexes of human immune responses, and the concentration of vitamin C is high in activated neutrophils and macrophages (5, 12, 32, 37, 39). Vitamin C also provides in vivo antioxidant protection primarily as an aqueous-phase peroxyl and oxygen radical scavenger and is concentrated in tissues and fluids with a high potential for radical generation (12). In response to physical trauma, vitamin C exerts a protective effect on neutrophil-mediated cell injury by scavenging reactive oxygen metabolites (9). Free-radical-mediated processes appear to be an important component of exercise-induced muscle and lymphoid tissue damage and inflammation (3).

Production of reactive oxygen species (ROS) during exhaustive exercise is well established (1, 2, 25, 31, 33, 36, 38). Several studies have indicated that vitamin C supplementation attenuates exercise-induced oxidative stress, but this is not a consistent finding (2, 29–31, 34, 38). ROS generation and antioxidant status may be linked to immune alterations after exercise, including cell adhesion, inflammation, and lymphocyte proliferation, and conversely, certain immune changes may contribute to oxidative stress (6, 33, 35). Several studies have produced conflicting data regarding the influence of vitamin C supplementation on immune changes after heavy exertion, and no data are presently available on how oxidative changes may influence this relationship. Three placebo-controlled investigations have shown that supplemental vitamin C (500–1,000 mg/day for 7–14 days) has no effect on a wide array of immune changes after intensive endurance exercise of 1- to 2.5-h duration (14, 21, 28). Two other studies with runners competing in the 90-km Comrades Ultramarathon showed an attenuation of postrace changes in serum cortisol, plasma cytokines, and leukocyte subset counts in subjects using vitamin C supplements (24, 26, 27). However, subjects in the two Comrades studies were not randomized to treatment groups, and carbohydrate intake was not controlled. Carbohydrate ingestion during prolonged and intensive exercise has strong influences on alterations in cortisol, immune cell counts, and anti-inflammatory cytokines (19, 20, 22, 23). Another potential explanation for the disparity in study outcomes is that vitamin...
C supplementation may not influence immunity after exercise until ultradistances are achieved. The purpose of this study was to measure the influence of vitamin C compared with placebo supplementation on oxidative and immune changes in ultramarathoners competing in an ultramarathon race. To improve on previous studies, subjects were randomized to treatment groups, and carbohydrate intake was carefully controlled. We hypothesized that vitamin C supplementation would attenuate changes in oxidative and immune measures during and after an ultramarathon race.

METHODS

Subjects. Ultramarathon runners were recruited through a letter of invitation before the April 7, 2001, Umstead Ultramarathon, in Raleigh, North Carolina. The Umstead Ultramarathon is conducted on a 16-km loop that is run five times for the 80-km race. Male and female runners ranging in age from 20 to 70 yr were accepted into the study if they had run at least one competitive ultramarathon and were willing to adhere to all aspects of the research design, including randomization to either the vitamin C or placebo group. Informed consent was obtained from each subject, and the experimental procedures were in accordance with the policy statements of the institutional review board of Appalachian State University.

Research design. Four to six weeks before the ultramarathon race event, subjects reported to the Appalachian State University human performance laboratory for orientation and measurement of body composition and cardiorespiratory fitness. Basic demographic and training data were obtained through a questionnaire. Runners agreed to avoid the use of large-dose vitamin and/or mineral supplements (above 100% of recommended dietary allowances), herbs, and medications known to affect immune function for 1 mo before the race. Runners also agreed to avoid ingesting anti-inflammatory medications the day before or during the race. During orientation, a dietician instructed the runners to follow a diet high in carbohydrates and moderate in vitamin C during the 7 days before the race event (through use of a food list) and record intake in a food record.

Body composition was assessed from hydrostatic weighing, and maximal oxygen consumption was determined by using a graded maximal protocol adapted for runners as described in earlier studies from our group (19, 21–23). Oxygen uptake and ventilation were measured by using the MedGraphics CPX metabolic system (MedGraphics, St. Paul, MN). Maximal heart rate was measured by using a chest heart rate monitor (Polar Electro, Woodbury, NY).

Subjects were randomized to vitamin C or placebo groups. During the 7-day period before the race, subjects ingested three 500-mg tablets of vitamin C or placebo each day (one at each meal), and these tablets were administered in a double-blinded fashion (and verified with post-study surveys). Subjects avoided food or beverages containing calories or caffeine other than the carbohydrate beverage supplied by the research team for 6 h before race start.

On race day, 29 ultramarathon runners reported to the start area at 4:30–5:00 AM. After subjects were allowed to sit for 10–15 min, blood samples were collected. Body mass was measured, and a chest heart rate monitor was attached to each runner. Runners received carbohydrate beverages with or without vitamin C in a double-blinded fashion by using a color code. The carbohydrate-vitamin C beverage contained vitamin C at a concentration of 150 mg/l. Carbohydrate beverages, with or without vitamin C, were supplied by the Gatorade Sports Science Institute (Barrington, IL) as in earlier studies (19–23). Each runner ingested 750 ml of beverage ~30 min before the start of the race (5:30 AM) and one 500-mg vitamin C or placebo tablet. During the race, runners drank ~1,000 ml of beverage each hour (60 g carbohydrate/h). Research assistants were positioned every 5 km (3 aid stations on the 16-km loop) to deliver color-coded beverage bottles that contained 500 ml of fluid (with or without vitamin C). Runners ingested the fluid from two bottles per hour, and also ate two to three carbohydrate gel packs per hour (each containing 25 g). Runners agreed to avoid all other beverages and food before and during the race. Research assistants also recorded heart rates and ratings of perceived exertion (RPE; 6–20 scale) from each runner every 5 km.

After subjects ran 32 km, and then again after they crossed the 80-km-race finish line, subjects had blood and saliva samples collected in the seated position within 5 min (about 1 min to walk to the subject to the sample-collection area and get them seated, and then the blood was collected immediately during a 4-min timed saliva collection). Because of extreme environmental conditions (see Results), some runners were unable to complete the race due to fatigue or the 12-h limit (imposed by the research team), and blood and saliva samples were collected from these runners as long as they had run 50 km or more. Body mass was also measured at 32 km and postrace. A postrace questionnaire verified compliance to all aspects of the research design by each runner.

Blood cell counts, hormones, glucose, and uric acid. Blood samples were drawn from an antecubital vein with subjects in the seated position. Routine complete blood counts and comprehensive diagnostic chemistries were performed by a clinical hematology laboratory (Lab Corp, Burlington, NC) and provided leukocyte subset counts, hemoglobin, hematocrit, and uric acid. Other blood samples were centrifuged in sodium heparin tubes, and plasma was aliquoted and then stored at −80°C. Plasma cortisol was assayed by using the competitive solid-phase 125I RIA technique (Diagnostic Products, Los Angeles, CA). RIA kits were also used to determine plasma concentrations of insulin and growth hormone according to manufacturer’s instructions (Diagnostic Products). Plasma was analyzed spectrophotometrically for glucose. Plasma volume changes were estimated by using the method of Dill and Costill (8).

Oxidative measurements. Blood samples were immediately centrifuged at 4°C for 10 min. Plasma was aliquoted into cryotubes and snap frozen in liquid nitrogen. Samples were stored at −80°C until analysis. F2-isoprostane was analyzed by gas chromatography mass spectrometry (17). Lipid hydroperoxides (ROOH) were analyzed by using a spectrophotometric kit provided by Caymen Chemicals (catalog no. 705002) (Ann Arbor, MI). The interassay coefficient of variation was <5%, and intra-assay coefficient of variation was <10%.

Lymphocyte subsets. The proportions of T cells (CD3+), B cells (CD19+), and natural killer cells (CD3−CD16+CD56+) were determined in whole blood preparations, and absolute numbers were calculated by using complete blood count data to allow group comparisons of lymphocyte subset concentrations. Lymphocyte phenotyping was accomplished by two-color fluorescent labeling of cell surface antigens with mouse anti-human monoclonal antibodies conjugated to FITC and phycoerythrin (PE) by using TriTEST reagents (Becton Dickinson, San Jose, CA). For immunophenotyping, 50-μl aliquots of heparinized whole blood from each sample were added to two 12 × 75-mm polystyrene test tubes. Twenty
microliters of CD3/CD16 + CD56/CD45 (BD Immunocyto-
metry Systems, catalog no. 340300) or CD3/CD19/CD45 (BD
Immunocytochemistry Systems, catalog no. 340381) were added
to individual tubes of the two tube panels, and the samples
were gently vortexed. After a 15-min incubation in the dark
at room temperature, the red blood cells were lysed by adding
450 µl of 1× FACS lysing solution (BD Immunocyto-
metry, catalog no. 349202). The tubes were gently vortexed and
incubated in the dark at room temperature for 15 min.
Samples were kept at 4°C in the dark until analyzed by flow
cytometry (FACSort, Becton Dickinson).

Cytokine measurements. Total plasma concentrations of
interleukin (IL)-1 receptor antagonist (IL-1Ra), IL-6, IL-8,
and IL-10 were determined by using quantitative sandwich
ELISA kits provided by R&D Systems (Minneapolis, MN). All
samples and provided standards were analyzed in duplicate.
A high-sensitivity kit was used to analyze IL-6 in the prerace
plasma samples. A standard curve was constructed by using
standards provided in the kits, and the cytokine concentra-
tions were determined from the standard curves by using
linear regression analysis. The assays were a two-step “sand-
wich” enzyme immunoassay in which samples and standards
were incubated in a 96-well microtiter plate coated with
polyclonal antibodies for the test cytokine as the capture
antibody. After the appropriate incubation time, the wells
were washed, and a second detection antibody was either
conjugated to alkaline phosphatase (IL-6 high sensitivity) or
had horseradish peroxidase (IL-1Ra, IL-6, IL-8, IL-10) added.
The plates were incubated and washed, and the amount of
bound enzyme-labeled detection antibody was measured by
adding a chromogenic substrate. The plates were then read
at the appropriate wavelength (450–570 nm for IL-1Ra, IL-6,
IL-8, and IL-10; 490–650 nm for IL-6 high sensitivity). The
minimum detectable concentration of IL-1Ra was <22 pg/ml,
IL-6 <0.70 pg/ml, IL-6 high sensitivity <0.094 pg/ml, IL-
8 <10 pg/ml, and IL-10 <3.9 pg/ml.

Phytohemagglutinin-induced lymphocyte proliferation and
cytokine production. The mitogenic response of lymphocytes
was determined in whole blood culture by using phytohemag-
glutinin (PHA) at optimal and suboptimal doses previously
determined by titration experiments. Heparinized venous
blood was diluted 1:10 with complete media consisting of
RPMI 1640 supplemented with 5% heat-inactivated fetal
bovine serum, penicillin, streptomycin, 1-glutamine, β-mer-
captoethanol, and Mito+ serum extender (BD Labware, cat-
alog no. 355006). PHA was prepared in RPMI 1640 media at
a concentration of 1 mg/ml and then further diluted with
complete media to the optimal and suboptimal working con-
centrations (25 µg/ml and 3.13 µg/ml, respectively). A 100-µl
aliquot of the diluted blood was dispensed into each of tripli-
cicate wells of a 96-well flat-bottom microtiter plate. To each
well, 100 µl of the appropriate mitogen dose were added.
Control wells received complete media instead of mitogen.
After 72-h incubation at 37°C and 5% CO2, a 100-µl aliquot of
the supernatant was removed from each well and immedi-
ately frozen at −20°C for cytokine analyses. The cells were
then pulsed with 1 µCi of thymidine-(methyl-3H) (New En-
gland Nuclear, Boston, MA) prepared with RPMI 1640. After
pulsing, cells were incubated for an additional 4 h before
harvesting. Radionucleotide incorporation was assessed by
liquid scintillation counting with the results expressed as
experimental minus control counts per minute. PHA-induced
proliferation expressed on a “per T cell” basis was calculated by
dividing the counts per minute data by the number of T
cells in the assay wells. Concentrations of secreted interferon
(IFN)-γ and IL-2 were determined from the frozen cell super-
natants by using quantitative sandwich ELISA kits provided
by R&D Systems. At the time of cytokine evaluation, the
supernatants were diluted 10- to 35-fold due to the expected
high concentration of cytokines in the samples (on the basis
of proliferation data). This was necessary to bring the con-
centration within the interpolating range of the respective
standard curve. The minimum detectable concentration for
IFN-γ was <8 pg/ml and for IL-2 was <7 pg/ml.

Statistical analysis. Statistical significance was set at the
P < 0.05 level, and values were expressed as means ± SE.
Vitamin C and placebo groups were compared for subject
characteristics and race performance measures by using in-
dependent t-tests (Tables 1 and 2). Leukocyte subset counts,
oxidative and cytokine measures, mitogen-stimulated lym-
phocyte proliferation and cytokine production, and hormone
values were analyzed by using 2 (vitamin C and placebo
groups) × 3 (times of measurement) repeated-measures
ANOVA. When Box’s M suggested that the assumptions
necessary for the univariate approach were not tenable, a
multivariate approach to repeated-measures ANOVA was
used. In the latter case, the Pillai’s trace statistic was used as
the test statistic. If the group × time interaction P value was
≤0.05, the change from baseline for the 32-km and postrace
values was calculated and compared between groups by us-
ing Student’s t-tests. For these two multiple comparisons
across groups, a Bonferroni adjustment was made, with sta-
tistical significance set at P < 0.025. Pearson product-mo-
cent correlations were used to test the relationship between
postrace measurements.

RESULTS

Eighty-two ultramarathoners fully complied with all
protocol requirements (Table 1). This included 15
runners in the vitamin C group and 13 runners in the
placebo group. Age, stature, body mass, running and
racing experience, and cardiorespiratory fitness did not
differ significantly between groups. The prereace diet
measured from 7-day food records did not differ signifi-
cantly between groups, with a mean energy intake of
11.2 ± 0.2 MJ/day, carbohydrate intake of 55.3 ± 2.8%
total energy, fat intake of 29.0 ± 1.8% total energy, and
vitamin C intake of 147 ± 24 mg/day.

Environmental conditions at the 6:00 AM race start
were 18°C and 90% relative humidity (RH), at 10:00
AM were 24°C and 60% RH, at 2:00 PM were 31°C and
40% RH, and at 6:00 PM were 30°C and 40% RH.
Ultramarathon race performance measurements are

Table 1. Subject characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Vitamin C (n = 15)</th>
<th>Placebo (n = 13)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, yr</td>
<td>49.9 ± 3.5</td>
<td>45.2 ± 2.8</td>
<td>0.312</td>
</tr>
<tr>
<td>Stature, m</td>
<td>1.73 ± 0.02</td>
<td>1.74 ± 0.02</td>
<td>0.642</td>
</tr>
<tr>
<td>Body mass, kg</td>
<td>76.8 ± 2.44</td>
<td>76.4 ± 2.8</td>
<td>0.912</td>
</tr>
<tr>
<td>Running experience, yr</td>
<td>14.3 ± 2.3</td>
<td>13.7 ± 2.5</td>
<td>0.852</td>
</tr>
<tr>
<td>Training distance, km/wk</td>
<td>58.9 ± 9.7</td>
<td>70.3 ± 5.6</td>
<td>0.321</td>
</tr>
<tr>
<td>Ultramarathons raced</td>
<td>21.2 ± 8.1</td>
<td>20.3 ± 6.6</td>
<td>0.934</td>
</tr>
<tr>
<td>VO2max, ml·kg·min⁻¹·1⁻¹</td>
<td>47.2 ± 1.8</td>
<td>48.4 ± 2.3</td>
<td>0.693</td>
</tr>
<tr>
<td>VEmax, l/min</td>
<td>134 ± 6</td>
<td>137 ± 6</td>
<td>0.689</td>
</tr>
<tr>
<td>HRmax, beats/min</td>
<td>181 ± 4</td>
<td>183 ± 4</td>
<td>0.725</td>
</tr>
<tr>
<td>RERmax</td>
<td>1.15 ± 0.02</td>
<td>1.16 ± 0.02</td>
<td>0.841</td>
</tr>
</tbody>
</table>

Values are means ± SE. VO2max, maximal oxygen consumption; VEmax, maximal exercise ventilation; HRmax, maximum heart rate; RERmax, maximum respiratory exchange ratio.
summarized in Table 2. Subjects in both groups maintained an intensity of ~75% of maximum heart rate throughout the ultramarathon race and ran a mean of 69 km (range of 48–80 km) in 9.8 h (range of 5–12 h). Ratings of perceived exertion averaged 11 ("fairly light") during the first 15 km and rose to just over 15 ("hard") by the end of the race. Fluid intake was close to the 1 liter/h goal throughout the race (mean intake of 57 g carbohydrate/h), resulting in modest changes in body mass and plasma volume. Runners also averaged 2.3 ± 0.2 gel packs or 58 g carbohydrate/h.

Plasma ascorbic acid was markedly higher in the vitamin C compared with placebo group and rose more strongly in the vitamin C group during the race (Fig. 1). Serum uric acid (Table 3) was negatively correlated with plasma ascorbic acid postrace (r = −0.47, P = 0.012), and uric acid was significantly lower in the vitamin C compared with placebo group (group effect across time points, P = 0.002). No significant group or interaction effects were measured for lipid hydroperoxide and F2-isoprostane, but both oxidative measures rose significantly during the ultramarathon race (Table 3). Postrace lipid hydroperoxide and F2-isoprostane were positively correlated (r = 0.44, P = 0.019). F2-isoprostane tended to be higher in the vitamin C compared with placebo group across all time points (group effect, P = 0.051). No significant interaction effects were measured for serum glucose and insulin, which tended to rise at 32 km and then fall closer to prerace levels by race end. Serum cortisol rose strongly in both groups during the race, with a slightly greater increase measured in the vitamin C group.

No significant group or interaction effects were measured for immune cell counts (Table 4). Neutrophil and monocyte counts rose in both groups during the race, with a decrease measured for T cell and natural killer lymphocyte counts. Plasma cytokine concentrations rose strongly during the race, but no significant group or interaction effects were measured (Table 5). Mitogen-stimulated lymphocyte proliferation (PHA, 25 μg/ml; Fig. 2) and IL-2 and IFN-γ production (Table 5) decreased strongly during the race (68, 63, and 72%, respectively), but no significant group or interaction effects were measured. Figure 2B shows that mitogen-stimulated lymphocyte proliferation adjusted for changes in T-cell counts was still 57% below prerace levels after the race (all subjects combined). Similar findings were found for mitogen-stimulated lymphocyte proliferation at a PHA concentration of 3 μg/ml (data not shown).

Postrace serum cortisol was positively correlated to serum vitamin C (r = 0.50, P = 0.006) and IL-10 (r = 0.65, P < 0.001), postrace F2-isoprostane was positively correlated to IL-10 (r = 0.42, P = 0.026), but no other significant correlations were found between se-

### Table 2. Race performance measures

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Vitamin C (n = 15)</th>
<th>Placebo (n = 13)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Average HR, beats/min</td>
<td>135 ± 4</td>
<td>136 ± 5</td>
<td>0.885</td>
</tr>
<tr>
<td>Average %HRmax</td>
<td>75.7 ± 1.9</td>
<td>75.2 ± 2.1</td>
<td>0.852</td>
</tr>
<tr>
<td>End RPE</td>
<td>14.3 ± 1.2</td>
<td>15.0 ± 1.8</td>
<td>0.677</td>
</tr>
<tr>
<td>Race distance, km</td>
<td>68.7 ± 3.3</td>
<td>68.7 ± 3.5</td>
<td>0.993</td>
</tr>
<tr>
<td>Race time, h</td>
<td>9.85 ± 0.36</td>
<td>9.68 ± 0.66</td>
<td>0.820</td>
</tr>
<tr>
<td>Fluid intake, 1/hr</td>
<td>1.04 ± 0.08</td>
<td>0.85 ± 0.06</td>
<td>0.067</td>
</tr>
<tr>
<td>Body mass loss, kg</td>
<td>−1.88 ± 0.37</td>
<td>−1.79 ± 0.24</td>
<td>0.850</td>
</tr>
<tr>
<td>Plasma volume change, %</td>
<td>−4.02 ± 0.48</td>
<td>−2.74 ± 0.55</td>
<td>0.088</td>
</tr>
</tbody>
</table>

Values are means ± SE. HR, heart rate; RPE, rating of perceived exertion.

### Table 3. Oxidative measures, plasma glucose, and hormones

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Prerace</th>
<th>32 km</th>
<th>Postrace</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lipid hydroperoxide, µM</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitamin C</td>
<td>31.3 ± 2.1</td>
<td>32.1 ± 2.3</td>
<td>39.8 ± 4.4</td>
</tr>
<tr>
<td>Placebo</td>
<td>36.3 ± 0.7</td>
<td>27.0 ± 3.1</td>
<td>39.2 ± 3.6</td>
</tr>
<tr>
<td>F2-isoprostane, pg/ml</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitamin C</td>
<td>60.4 ± 8.2</td>
<td>64.5 ± 7.0</td>
<td>75.1 ± 5.6</td>
</tr>
<tr>
<td>Placebo</td>
<td>44.8 ± 2.8</td>
<td>53.7 ± 4.0</td>
<td>62.6 ± 2.8</td>
</tr>
<tr>
<td>Uric acid, mg/dl</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitamin C</td>
<td>4.05 ± 0.34</td>
<td>3.51 ± 0.21</td>
<td>4.07 ± 0.29</td>
</tr>
<tr>
<td>Placebo</td>
<td>4.95 ± 0.31</td>
<td>5.02 ± 0.28</td>
<td>5.49 ± 0.32</td>
</tr>
<tr>
<td>Serum glucose, mmol/l</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitamin C</td>
<td>6.65 ± 0.16</td>
<td>7.94 ± 0.21</td>
<td>7.07 ± 0.46</td>
</tr>
<tr>
<td>Placebo</td>
<td>8.14 ± 0.78</td>
<td>8.95 ± 0.54</td>
<td>7.67 ± 0.55</td>
</tr>
<tr>
<td>Serum insulin, pmol/l</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitamin C</td>
<td>35.8 ± 2.8</td>
<td>74.8 ± 13.3</td>
<td>39.6 ± 5.4</td>
</tr>
<tr>
<td>Placebo</td>
<td>59.3 ± 10.9</td>
<td>96.6 ± 16.8</td>
<td>53.0 ± 6.9</td>
</tr>
<tr>
<td>Serum cortisol, nmol/l</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitamin C</td>
<td>583 ± 28</td>
<td>664 ± 68</td>
<td>1293 ± 142</td>
</tr>
<tr>
<td>Placebo</td>
<td>678 ± 40</td>
<td>750 ± 58</td>
<td>1014 ± 101</td>
</tr>
</tbody>
</table>

Values are means ± SE.

![Graph](image-url)
rum vitamin C, oxidative, hormonal, and immune measures.

**DISCUSSION**

Runners in this study were able to maintain an intensity of ~75% maximal heart rate for nearly 10 h during an unexpectedly hot spring day. Vitamin C compared with placebo supplementation (1,500 mg/day for 7 days before and the day of the ultramarathon race) was associated with elevated plasma vitamin C and diminished uric acid levels but had no consistent influence on postrace oxidative or immune alterations. This is the first study to test the influence of vitamin C supplementation on measures of both oxidative and immune stress after a competitive race. Except for a positive correlation between F2-isoprostane and plasma IL-10, no other significant correlations were found between postrace plasma vitamin C, oxidative, and immune measures.

These data are in agreement with three other studies that also reported no differences in immune changes between vitamin C and placebo groups after heavy exertion (14, 21, 28). In a previous study in our laboratory (21), 12 marathoners ran for 2.5 h on treadmills under vitamin C or placebo conditions (1,000 mg/day for 8 days), and no differences were measured in hormonal and immune measures (including natural killer cell activity, mitogen-stimulated lymphocyte prolifera-

**Table 4. Immune cell counts**

<table>
<thead>
<tr>
<th>Cell count, 10^9</th>
<th>Prerace</th>
<th>32 km</th>
<th>Postrace</th>
<th>Effect: Group Interaction</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neutrophils</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitamin C</td>
<td>2.84 ± 0.21</td>
<td>5.97 ± 0.44</td>
<td>11.43 ± 0.85</td>
<td>0.942</td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>2.95 ± 0.22</td>
<td>5.92 ± 0.55</td>
<td>11.25 ± 0.73</td>
<td>0.958</td>
<td></td>
</tr>
<tr>
<td>Monocytes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitamin C</td>
<td>0.32 ± 0.02</td>
<td>0.28 ± 0.04</td>
<td>0.65 ± 0.07</td>
<td>0.597</td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>0.32 ± 0.03</td>
<td>0.28 ± 0.05</td>
<td>0.79 ± 0.14</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Total lymphocytes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitamin C</td>
<td>2.02 ± 0.14</td>
<td>1.43 ± 0.06</td>
<td>1.57 ± 0.15</td>
<td>0.942</td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>2.03 ± 0.15</td>
<td>1.46 ± 0.15</td>
<td>1.55 ± 0.13</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>T lymphocytes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitamin C</td>
<td>1.44 ± 0.10</td>
<td>1.02 ± 0.06</td>
<td>1.03 ± 0.11</td>
<td>0.879</td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>1.41 ± 0.10</td>
<td>1.05 ± 0.11</td>
<td>1.04 ± 0.08</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>B lymphocytes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitamin C</td>
<td>0.19 ± 0.02</td>
<td>0.15 ± 0.01</td>
<td>0.19 ± 0.02</td>
<td>0.929</td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>0.21 ± 0.03</td>
<td>0.16 ± 0.02</td>
<td>0.22 ± 0.03</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Natural killer lymphocytes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitamin C</td>
<td>0.35 ± 0.07</td>
<td>0.23 ± 0.04</td>
<td>0.31 ± 0.05</td>
<td>0.655</td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>0.36 ± 0.04</td>
<td>0.21 ± 0.02</td>
<td>0.27 ± 0.04</td>
<td>&lt;0.001</td>
<td></td>
</tr>
</tbody>
</table>

Values are means ± SE.

**Table 5. Plasma cytokines and mitogen-stimulated cytokine production**

<table>
<thead>
<tr>
<th>Cytokine, pg/ml</th>
<th>Prerace</th>
<th>32 km</th>
<th>Postrace</th>
<th>Effect: Group Interaction</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL-6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitamin C</td>
<td>1.3 ± 0.2</td>
<td>10.8 ± 2.8</td>
<td>46.5 ± 5.1</td>
<td>0.304</td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>1.3 ± 0.2</td>
<td>11.0 ± 2.0</td>
<td>36.1 ± 6.3</td>
<td>0.202</td>
<td></td>
</tr>
<tr>
<td>IL-1RA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitamin C</td>
<td>170 ± 12</td>
<td>388 ± 33</td>
<td>958 ± 106</td>
<td>0.777</td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>204 ± 25</td>
<td>410 ± 50</td>
<td>1,176 ± 289</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>IL-10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitamin C</td>
<td>3.0 ± 0.4</td>
<td>4.4 ± 1.6</td>
<td>17.1 ± 5.3</td>
<td>0.192</td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>3.1 ± 0.4</td>
<td>7.9 ± 3.0</td>
<td>13.8 ± 3.4</td>
<td>0.003</td>
<td></td>
</tr>
<tr>
<td>IL-8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitamin C</td>
<td>7.9 ± 1.3</td>
<td>16.4 ± 1.6</td>
<td>28.5 ± 3.5</td>
<td>0.892</td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>8.7 ± 2.3</td>
<td>18.0 ± 1.8</td>
<td>28.1 ± 3.9</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>IL-2, PHA 25 μg/ml</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitamin C</td>
<td>140.3 ± 31.8</td>
<td>95.9 ± 18.7</td>
<td>46.1 ± 12.8</td>
<td>0.094</td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>79.5 ± 22.2</td>
<td>49.0 ± 7.1</td>
<td>36.6 ± 5.0</td>
<td>0.188</td>
<td></td>
</tr>
<tr>
<td>IFN-γ, PHA 25 μg/ml</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitamin C</td>
<td>2,414 ± 266</td>
<td>1,269 ± 207</td>
<td>638 ± 167</td>
<td>0.240</td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>1,906 ± 260</td>
<td>948 ± 205</td>
<td>570 ± 167</td>
<td>&lt;0.001</td>
<td></td>
</tr>
</tbody>
</table>

Values are means ± SE. IL, interleukin; IL-1RA, IL-1-receptor antagonist; PHA, phytohemagglutinin; IFN, interferon.
liferation, granulocyte/monocyte phagocytosis and oxidative burst activity, leukocyte subsets, and IL-6). Krause et al. (14) reported no effects of vitamin C supplementation (2,000 mg for 1 wk) on neutrophil phagocytosis and bactericidal ability in six men after a competitive biathlon (16-km uphill cycling and 2-km uphill running). However, that study did not include a placebo supplement, and subjects were not randomized to treatment conditions. In another investigation (28), 20 male runners took 500 mg of vitamin C and 400 mg of vitamin E or placebo for 14 days before and 7 days after running downhill for 90 min on treadmills. Despite a substantial elevation in plasma levels of vitamins C and E, no groups differences were measured for cytokines and lymphocyte subsets, and the authors concluded that exercise-induced inflammatory responses are not induced by free oxygen radicals. However, in that study, no measures of oxidative stress were reported.

In a study of 29 ultramarathon runners competing in the Comrades 90-km race, vitamin C compared with placebo supplementation did attenuate postrace increases in cortisol, epinephrine, leukocyte subset counts, and cytokines (24, 26). These results differ markedly from the present study, and several explanations are possible. In the Comrades study, subjects were not randomized to treatment groups, and carbohydrate intake during the race was ad libitum and retrospectively estimated, in contrast to methods followed in the present study (24, 26). Carbohydrate compared with placebo beverage ingestion has a marked effect on postexercise changes in stress hormones and immunity, in particular, those related to inflammation, including cortisol, pro- and anti-inflammatory cytokines (IL-6, IL-10, IL-1Ra), neutrophil and monocyte cell counts, and granulocyte/monocyte phagocytosis and oxidative burst activity (19, 20, 22, 23). Carbohydrates have little influence on salivary IgA and measures related to adaptive immunity, including mitogen-stimulated lymphocyte proliferation and cytokine production by isolated cells in vitro (20). In the present study, all ultramarathon runners used carbohydrate beverages and gels, ingesting an average of 115 g/h, thus keeping serum glucose concentrations at a high level and preventing a typical exercise-induced decrease in insulin. This high intake of carbohydrates was more than likely responsible for the modest perturbations in leukocyte subset cell counts and anti-inflammatory cytokines (i.e., modest compared with changes in these immune measurements we have measured in the placebo state after a competitive marathon race or 2.5 h of running or cycling in the lab) (22, 23). In contrast, the decrease in mitogen-stimulated lymphocyte proliferation and cytokine production for all subjects combined was greater than in all of our previous laboratory and field studies.

ROOH are formed from the oxidative conversion of polyunsaturated fatty acids and are one of the major initial reactants of lipid peroxidation. If not terminated by antioxidants, the chain of peroxidation events can become self-perpetuating, resulting in steadily increased levels of ROOH. ROOH are toxic and capable of damaging most body cells (18). In addition to the nutrient antioxidants vitamins E and C, catalase and glutathione peroxidase are endogenous antioxidant enzymes that neutralize ROOH. Typically, unless glutathione peroxidase or catalase are overwhelmed or inhibited, ROOH will not accumulate in plasma or other tissues. Studies that have found increased ROOH usually required subjects to exercise to exhaustion (1, 36). In the present study, ROOH were slightly elevated in the runners postrace, implying that antioxidant activities were sufficient to prevent a large increase in ROOH (7, 25).

Unlike ROOH, F2-isoprostanes are stable prostaglandin-like compounds produced by free radical catalyzed peroxidation of arachidonic acid, independent of the cyclooxygenase pathway. Another interesting aspect is that F2-isoprostanes are formed esterified to phospholipids in vivo and possess potent biological activity such as vasoconstriction of smooth muscle and stimulation of platelet aggregation (10, 17). As such, F2-isoprostanes may serve as mediators of oxidant stress (10). F2-isoprostane values were significantly increased during running in both the vitamin C and placebo groups. This indicates that the ultramarathon run induced oxidative stress. We believe this is the first study to report plasma F2-isoprostanes in exercising humans.

F2-isoprostanes are known to increase intracellular calcium levels in cells expressing thromboxane receptors (15, 17). Additionally, many types of immune cells are known to be activated by intracellular calcium signaling (10, 13, 16). Although we found no statistical correlation between immune variables and oxidative stress, with the exception of a weak association between IL-10 and F2-isoprostane values, the possibility exists that F2-isoprostanes may influence or modulate immune function.

There is limited evidence that exercise-induced oxidative stress is related to alterations in immune function. Oxidants may directly and indirectly induce cell adhesion, thereby influencing the inflammatory process (33). In one study of 19 men engaging in exhaustive exercise, significant correlations were reported between oxidative stress measures and mitogen-induced lymphocyte proliferation and acute phase response (35). Strenuous physical exercise of limb muscles typically results in muscle soreness and injury, especially during intensive, prolonged exercise, such as ultramarathon race competition. During heavy exertion, the unusual metabolic demands cause an increase in ROS generation, in part due to the influx of neutrophils into muscle tissues, which are a major source of extracellular ROS. ROS causes a wide spectrum of cellular damage and may mediate leukocyte apoptosis (3).

There is some evidence that vitamin C protects cells from oxidative damage, thereby reducing inflammation and cytokine production (4, 6, 32). Neutrophil ROS have a damaging effect on the neutrophils themselves, and, for protection, these cells acquire a high level of ascorbic acid (39). However, the relationship between
vitamin C supplementation, muscle soreness, and oxidative stress is not clear at this time. In a study of highly trained runners (31), 1 g of vitamin C ingested immediately before a 4-h race inhibited oxidation of low-density lipoprotein. Thoroughbred racehorses treated intravenously with 5,000 mg of vitamin C before a 1,000-m race at maximal velocity experienced less oxidative stress but similar muscle damage to untreated horses (38). In contrast, sled dogs given vitamin C and C supplements or placebo during 3 days of intensive exercise experienced similar postexercise changes in measures of oxidative stress and muscle damage (29). Marathon runners given vitamin E and C supplements or placebos for 4.5 wk before a competitive marathon race experienced lower creatine kinase but similar postrace changes in lipid peroxidation (30). In another study, 1,000 mg of vitamin C compared with placebo ingestion 2 h before 90 min of intermittent shuttle-running did not influence markers of both muscle damage and lipid peroxidation (34). Thus vitamin C supplementation before prolonged and intensive exercise does not have a consistent effect on blood measures of oxidative stress and muscle damage, and any linkage to immune perturbations remains speculative and more than likely improbable.

In summary, our data indicate that vitamin C supplementation does not serve as a countermeasure to postexercise oxidative and immune changes in carbohydrate-fed ultramarathon runners. Statistical correlations suggest that oxidative stress had little influence on the immune changes that take place during or after a competitive ultramarathon race.

This work was funded by the Gatorade Sports Science Institute and National Institutes of Health Grants (to J. D. Morrow) DK-48831, GM-15431, CA-77839, and DK-26657. J. D. Morrow is the recipient of a Burroughs Wellcome Fund Clinical Scientist Award in Translational Research.

REFERENCES


